BeyondSpring Inc.

NASDAQ:BYSI

Biotechnology

Healthcare
$1.25 +1.58%

+$0.03 today

Market cap
$51.40M
Beta
0.42
P/E (TTM)
-8.7
EPS (TTM)
-$0.19
52W Low $1.18High $3.28

Volume 0.01M

Average 0.02M

BYSI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

BeyondSpring Inc.NASDAQ: BYSI

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$2.14M, compared with -$2.48M a year earlier. Trailing-twelve-month EBITDA was -$8.02M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of $38.93M (+556.0%) for the fiscal year ending Dec 2026, a step up from the -0.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$2.14M+13.2% QoQ
Last fiscal yearDec 2025
-$8.54M-0.6% YoY
LTMMar 2026
-$8.02M-9.0% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.8%+198.8%+185.0 pp
1 year-0.6%+556.0%+556.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(8.54M) USD
Year-over-year change
-0.6%
Reported Analyst consensus estimate

EBITDA vs competitors

How BYSI compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -9.0% is the 5th highest of 9, against a peer median of -5.9%.
BYSI Competitors
EBITDA for BYSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BYSIBeyondSpring Inc.LTM Mar 2026-$8.02M USD-9.0%——
HYFTMindWalk Holdings Corp.LTM Jan 2026-CA$10.88M CAD+76.6%—59.3%
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026-$39.25M USD-164.0%——
DTILPrecision BioSciences, Inc.LTM Mar 2026-$40.42M USD-143.9%—89.7%
BMEABiomea Fusion, Inc.LTM Mar 2026-$46.12M USD+63.6%——
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026-$52.24M USD-1.2%—1327.8%
ATYRaTyr Pharma, Inc.LTM Mar 2026-$68.69M USD-10.6%—36154.2%
ALXOALX Oncology Holdings Inc.LTM Mar 2026-$86.7M USD+32.0%——
GUTSFractyl Health, Inc. Common StockLTM Mar 2026-$106.88M USD-21.2%——
Peer median (excluding BYSI) —-5.9%—708.7%

Competitors are the stored peer set for BYSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.35M1.35M000
Cost of Revenue00302K087K
Gross Profit1.35M1.35M(302K)0(87K)
Gross Margin100.0%100.0%———
Research & Development36.89M25.58M7.27M2.64M4.39M
Selling, General & Admin30.7M13.01M7.51M6.11M4.56M
Operating Expenses67.59M38.59M14.78M8.75M8.86M
Depreciation & Amortization61K1.14M302K285K87K
EBITDA(64.49M)(34.96M)(13.62M)(8.48M)(8.54M)
EBITDA Margin-4773.5%-2587.4%———
Operating Income(66.24M)(37.24M)(15.08M)(8.75M)(8.95M)
Operating Margin-4903.0%-2756.4%———
Interest Income98K195K421K59K78K
Interest Expense87K17K000
Other Income / Expenses1.6M1.12M1.16M(15K)320K
Income Before Tax(64.64M)(36.12M)(13.92M)(8.77M)(8.63M)
Pre-Tax Margin-4784.5%-2673.4%———
Income Tax Expense3.57M163K92K96K90K
Net Income(64.18M)(33.28M)(21.03M)(11.12M)(7.99M)
Net Margin-4750.5%-2463.3%———
EPS (Basic)(1.64)(0.85)(0.54)(0.28)(0.20)
EPS (Diluted)(1.64)(0.85)(0.54)(0.28)(0.20)
Weighted Avg Shares39.02M39.09M39M39.73M40.41M
Weighted Avg Shares (Diluted)39.02M39.09M39M39.73M40.41M

BeyondSpring Inc.

NASDAQ:BYSI

Intrinsic Alpha fair value

Locked

Current Price

$1.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.